Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the stage for the Chicago-based firm to submit the drug candidate for ...

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...